, CSL Behring, Bern, Switzerland) are injection site volume < _25 mL and flow rate < _25 mL/h/site. This open-label, multicenter, parallel-arm, non-randomized study will evaluate the tolerability of higher infusion parameters of IgPro20 using forced upward titration design. METHODS: Forty-five PID patients will be evaluated in three cohorts (n515/cohort): Pump-Assisted Volume (weekly infusions; injection volume 25/40/50 mL/site); Pump-Assisted Flow Rate (weekly infusions; infusion rate 25/50/75/100 mL/h/site); Manual Push Flow Rate (2-7 infusions/week; infusion rate 30/60/120 mL/h/site). Responders in the Pump-Assisted cohorts are those who tolerate > _3 of 4 infusions at each parameter level; in the Manual Push cohort, a similar definition was used, taking into account the variable infusion frequency. The primary endpoint is responder rate. Each parameter level will be tested for 4 weeks, after which responders will be switched to the next level. Weekly IgPro20 dose will remain as prescribed by the treating physician, usually 100-200 mg/ kg. Serum IgG trough levels will be assessed on Day 1 and at study end. In contrast, Gain-of-function (GOF) mutations in STAT3 have only recently been described. Individuals can present with immune dysregulation, multiorgan autoimmunity, autoimmune cytopenias, lymphoproliferation, and infections. Here we present two brothers with identical STAT3 GOF mutations but differing multisystem autoimmune conditions. METHODS: Brother #1 is a 20-year-old male with lymphocytic colitis, hypogammaglobulinemia requiring replacement therapy, chronic-recurrent reactive lymphadenopathy, and intermittent immune thrombocytopenia (DAT+). Infectious history is notable for two episodes of pneumonia treated as an outpatient. Brother #2 is an 18-year old male with p-ANCA vasculitis/microscopic polyangiitis diagnosed after severe pulmonary hemorrhage requiring ECMO, chronic kidney disease (necrotizing and crescentic glomerulonephritis) and short stature. Infectious history is notable for pulmonary coccidioidomycosis while on immune suppression. RESULTS: Brother #1 was found to have a STAT3 gain-of-function mutation (p.Thr716Met). Subsequently, brother #2 was tested and found to have the same mutation. Brother #1 is planned to start on medical therapy consisting of tocilizumab (anti-IL6), ruxolitinib (JAK inhibitor), and immunoglobulin replacement. Brother #2 is continuing azathioprine for vasculitis. Both are also under consideration for HSCT. CONCLUSIONS: STAT3 GOF mutations are associated with autosomaldominant multisystem immune dysregulation. Patients can be medically treated with JAK/STAT inhibitors to restore regulatory T-cell homeostasis. Allogeneic stem cell transplant is a curative option, with increased survivability when the patient's immune dysregulation is quiescent. These cases highlight the phenotypic variability of STAT3 GOF disorders in siblings with the same mutation. Further research is needed to delineate genotype-phenotype correlation.
